ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

UK Health Body Approves Novartis's Gilenya For MS

ZURICH -(Dow Jones)- The U.K.'s health-cost regulator is backing Novartis's (NVS) pill Gilenya for certain adult patients with highly active relapsing-remitting multiple sclerosis. The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it is recommending Gilenya, or fingolimod, for use on the publicly funded National Health Service. "We are pleased to recommend fingolimod as a treatment option for the specific patient population for whom it has been demonstrated to be cost-effective, providing Novartis applies its proposed discount," NICE Director Carol Longson said, without disclosing the price. Gilenya has been available in the European Union since March 2011 for treating relapsing-remitting MS, the most common type of the disease. The drug was approved in the U.S. in 2010. Novartis hopes the drug will become one of the leading treatments in the multibillion-dollar market for treating MS due to its easy oral use. "Novartis welcomes this final decision from NICE, which will allow appropriate patients with highly active relapsing-remitting MS to have access to Gilenya under the NHS in England and Wales," the company said in a statement, adding that it "remains committed to engaging with reimbursement authorities with the goal of ensuring that appropriate patients will have access to the treatment." Last week, EU and US regulators requested stronger label warnings for Gilenya after conducting reviews of the pill's safety, following reports of heart problems and the death of a patient. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
10/29/201411:53:10Norway's Oil Fund Posts Flat Returns in 3Q
10/29/201411:13:35Norway's Oil Fund Posts Flat Returns in 3Q--Update
10/28/201413:20:12EUROPE MARKETS: European Stocks Rebound; Stoxx 600 Up 1%
10/28/201406:05:25EUROPE MARKETS: European Stocks Rebound; Stoxx 600 Up 0.7%
10/26/201422:31:12CSL to Buy Novartis Influenza-Vaccine Unit
10/26/201418:49:15CSL to Buy Novartis Influenza-Vaccine Unit for $275 Million
10/23/201407:33:40Novartis 3Q 2014 -- Forecast
10/10/201404:08:25Oxford Biomedica Inks New Collaboration Pact with Novartis
10/03/201411:32:27EU Approves Acquisition of Novartis Animal Health Division by...
09/22/201412:43:39Germany's Merck to Buy Sigma-Aldrich for $17 Billion--2nd Update
09/01/201412:45:13EUROPE MARKETS: Novartis Climbs, Iliad Drops: European Movers
09/01/201412:01:47EUROPE MARKETS: Novartis Up, Iliad Drops: European Movers
09/01/201408:27:44Ruble Hits New Record Low Against Dollar
08/29/201412:46:16Zurich Stocks Rise; Novartis Drug Test Results Eyed -- Market...
08/18/201412:40:12Zurich Stocks Mostly Higher; Swisscom Down -- Market Talk
08/01/201412:26:48LONDON MARKETS: FTSE 100 Slumps For Third Day As Miners, Banks...
07/28/201402:37:21Novartis Gets EU Approval For Glaucoma Drug
07/25/201407:44:11Drug Companies Oppose Moves to Reimburse Off-Label Medicine
07/17/201418:27:37ADR Shares End Lower; SAP Shares Trade Actively
07/16/201418:17:45Novartis 2Q Results -- Forecast

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad